EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines. The reduced timeline is important for enabling their precision immunotherapy to treat patients in the neoadjuvant clinical setting, before surgical removal of their tumors.

Click Here to Read More